Work

Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors

Year: 2015

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-15-c45

Authors: Filip Janku, Roisin Connolly, Patricia LoRusso, Maya de Jonge, Ulka Vaishampayan, Jordi Rodon, Guillem Argilés, Andrea Myers, Shu-Fang Hsu Schmitz, Yan Ji, Margaret McLaughlin, Michael R. Palmer, Jennifer Morawiak

Institutions: The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center, Yale Cancer Center, Yale University, Erasmus MC, Erasmus MC Cancer Institute, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Novartis (Switzerland)

Language: English

Topic: Wnt/β-catenin signaling in development and cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2342086151

Cites:

Cited by: 27

Related to: 10